Results for tag: "Imlygic"

Imlygic is a type of skin cancer drug that is used to treat melanoma, a type of skin cancer. It is a type of oncolytic virus therapy, which uses a modified virus to target and destroy cancer cells. Imlygic is administered directly into the tumor, where it replicates and spreads to other cancer cells, destroying them in the process. It is also used to reduce the size of tumors and to reduce the risk of recurrence. Imlygic is approved by the US Food and Drug Administration (FDA) for the treatment of melanoma. The Imlygic market is composed of pharmaceutical companies that develop and market the drug. These companies include Amgen, Merck, and Bristol-Myers Squibb. Other companies involved in the market include Genentech, Novartis, and GlaxoSmithKline. These companies are involved in the research, development, and marketing of Imlygic. They are also involved in the clinical trials and regulatory approval process for the drug. Show Less Read more